Clinical trials: Locoregionally Advanced Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
This study is a multicenter, randomized, controlled phase III clinical trial aiming to investigate the efficacy and safety of Becotatug Vedotin induction therapy followed by concurrent chemoradiotherapy (CCRT) combined with…
- Trial name
- NCT07459296
- Testing
- Becotatug Vedotin, Sintilimab, Cisplatin
- Where
- China
- Volunteers
- 266 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is commonly observed in southern China, particularly in the Pearl River delta area and the Xijiang River basin in the Guangdong and Guangxi provinces, with an incidence rate as high as 25-50 per…
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Cancer
- Trial name
- NCT04004871
- Testing
- Nab-paclitaxel, Cisplatin and Fluorouracil, concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangxi Medical University
Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma
Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
This is a phase 2, multicentre, open-label, randomised, controlled trial with a parallel-group design. The study aims to evaluate the efficacy and safety of single-agent Becotatug Vedotin as adjuvant therapy in patients with…
- Conditions
- Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma, Adjuvant Therapy
- Trial name
- NCT07303283
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Kai Hu
Nasopharyngeal Carcinoma
Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma
This is a prospective, single-center, single-arm, phase II clinical study. The study was intended to include patients with locoregionally advanced nasopharyngeal cancer identified by histology or cytology, who signed informed…
- Trial name
- NCT06364826
- Testing
- Sintilimab, bevacizumab, gemcitabine, IMRT
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma, Nutrition Therapy
Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition
This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy of standard nutrition treatment versus conventional nutrition treatment in local advanced…
- Trial name
- NCT04436965
- Testing
- Standardized nutrition therapy, Cisplatin, Intensity Modulated Radiation Therapy
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
MLN8237 in Head and Neck Cancer
This study will evaluate the initial safety and effectiveness of an investigational drug, MLN8237, added to routine radiation therapy and cetuximab in patients with head and neck cancer.
- Trial name
- NCT01540682
- Testing
- MLN8237, Cetuximab, Radiotherapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
1、Enough Cases, 2、Elekta Precise 1343 Digital Control Electron Linear Accelerator
Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer
1) Observe and compare the curative effect of endostatin/recombined Endostatin in alliance with neoadjuvant chemotherapy and Concurrent chemo-radio therapy to treat the local advanced nasopharyngeal darcinoma; 2) Evaluate the…
- Conditions
- 1、Enough Cases, 2、Elekta Precise 1343 Digital Control Electron Linear Accelerator, Can Undertake Nasopharyngeal Carcinoma Specimens in the Materia，, Image Department of Nose Pharynx Ministry MRI Dynamic Testing,
- Trial name
- NCT01689558
- Testing
- Recombine Endostatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jin Feng
Nasopharyngeal Carcinoma
Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
Patients with "high-risk" locoregionally-advanced nasopharyngeal carcinoma (LA-NPC), defined as AJCC/UICC 8th edition TNM-stage III-IVA and high Epstein-Barr virus (EBV) DNA viral load (≥4,000 copies/mL) will require induction…
- Trial name
- NCT06093061
- Testing
- CCRT with Maintenance Tislelizumab and Metronomic Capecitabine
- Where
- 2 sites in Singapore
- Volunteers
- 53 people
- Sponsor
- National Cancer Centre, Singapore
Nasopharyngeal Carcinoma
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
The purpose of this study is to compare concurrent chemoradiotherapy (CCRT) alone with induction chemotherapy (gemcitabine+cisplatin) plus CCRT in patients with low-risk locoregionally advanced nasopharyngeal carcinoma(NPC).
- Trial name
- NCT05979961
- Testing
- IMRT and concurrent cisplatin, gemcitabine and cisplatin (Induction chemotherapy)
- Where
- 8 sites in China
- Volunteers
- 464 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare induction chemotherapy (docetaxel+cisplatin+fluorouracil) plus concurrent chemoradiotherapy with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal…
- Trial name
- NCT01245959
- Testing
- Docetaxel, cisplatin and fluorouracil, Concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 476 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma
The investigators aim to evaluate the efficiency and toxicities of induction chemotherapy of docetaxel, cisplatin and xeloda in nomogram-predicted high risk locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT02786641
- Testing
- Docetaxel, Cisplatin 1, Xeloda
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC)
Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
This phase III randomized, double-blind, placebo-controlled trial evaluates whether nanocrystalline megestrol acetate can reduce anorexia in patients with locally advanced nasopharyngeal carcinoma (NPC) undergoing concurrent…
- Trial name
- NCT07796789
- Testing
- Nanocrystalline Megestrol Acetate Oral Suspension
- Where
- 3 sites in China
- Volunteers
- 204 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma
This is a Phase III trial to study the effectiveness of nedaplatin versus cisplatin with IMRT chemoradiotherapy in treating patients with locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT01540136
- Testing
- Nedaplatin, Cisplatin
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Neoplasms
Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
The CONTINUUM trial plans to enroll patients with stage III-IVA (AJCC 8th, except T3N0-1 or T4N0) locoregionally-advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- CONTINUUM (NCT03700476)
- Testing
- Sintilimab, Gemcitabine, Cisplatin
- Where
- 9 sites in China
- Volunteers
- 425 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Nedaplatin in Treatment for Nasopharyngeal Carcinoma
To evaluate the efficacy of induction chemotherapy with nedaplatin, docetaxel and 5-Fluorouracil followed by concurrent nedaplatin combined with radical radiotherapy in locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT04834206
- Testing
- Docetaxel, nedaplatin, fluorouracil, IMRT, Nedaplatin
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Nasopharyngeal Carcinoma
Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Several prospective randomized trials have demonstrated that concurrent chemoradiotherapy was superior to radiotherapy alone in the treatment of locoregionally advanced nasopharyngeal carcinoma (NPC).
- Trial name
- NCT02434614
- Testing
- Docetaxel,Cisplatin,Fluorouracil, Intensity-modulated radiation therapy (IMRT), Cisplatin
- Where
- 6 sites in China
- Volunteers
- 440 people
- Sponsor
- Wei Jiang
Nasopharyngeal Carcinoma
Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
A total of 300 patients with pathologically confirmed Locoregionally advanced nasopharyngeal carcinoma were enrolled. Patients were randomly divided into two groups, with 150 patients in each group.
- Trial name
- NCT02907710
- Testing
- Endostar, DDP
- Where
- China
- Volunteers
- 300 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma
Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Trial name
- NCT03025958
- Testing
- Nimotuzumab, Radiation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma (NPC)
PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
This study will enroll 664 patients who had completed induction chemotherapy combined with the PD-1 antibody sintilimab treatment followed by concurrent cisplatin-based chemoradiotherapy (no concurrent sintiliamb).
- Trial name
- NCT06900218
- Testing
- Sintilimab, Capecitabine
- Where
- China
- Volunteers
- 664 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
De-escalation Protocols in Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of image guided de-escalation protocols in patients with locoregionally advanced nasopharyngeal carcinoma (NPC).
- Trial name
- NCT04158518
- Testing
- Toxicities reduced treatment, Conventional treatment
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Chaosu Hu